Claim OwnershipFrom Our Neurons to Yours
Subscribed: 84Played: 673
Subscribe
© 2025 Wu Tsai Neurosciences Institute, Stanford University
Description
This award-winning show from Stanford’s Wu Tsai Neurosciences Institute is a field manual for anyone who wants to understand their own brain and the new science reshaping how we learn, age, heal, and make sense of ourselves.
Each episode, host Nicholas Weiler sits down with leading scientists to unpack big ideas from the frontiers of the field—brain-computer interfaces and AI language models; new therapies for depression, dementia, and stroke; the mysteries of perception and memory; even the debate over free will. You’ll hear how basic research becomes clinical insight and how emerging tech might expand what it means to be human. If you’ve got a brain, take a listen.
63 Episodes
Reverse
Most of us can agree: music is awesome. Regardless of which songs speak to you, music probably plays an important role in your life. The question is, what makes music so powerful? Why does a particular combination of sounds and rhythms grab us and affect us in the way that it does? And is it true that music can help heal patients with Alzheimer's, Parkinson's, PTSD, chronic pain, and more? To help us understand what we're learning about the neuroscience of music and how it can heal and ...
In this episode, we explore the fascinating neuroscience behind how children learn to read with Bruce McCandliss, director of the Stanford Educational Neuroscience Initiative. Key topics include: • How our brains "recycle" visual and language circuits to create reading expertise • The crucial threshold when reading shifts from effortful to automatic • Why some children struggle more than others to develop reading fluency • How teachers can tailor instruction to help struggling readers • The p...
Recognizing a familiar voice is one of the brain’s earliest social feats. But what are the brain circuits that let a newborn pick out mom in a crowded nursery? How do they change as kids turn toward friends and the wider world? And what are we learning about why this instinct fails to develop in the autistic brain? This week, host Nicholas Weiler joins Stanford neuroscientist Dan Abrams on the quest to understand the neural “hub” that links our brains' hearing centers to the networks that tag...
If addiction is a disease of the brain, what does that mean for how we treat people—and how we write policy? In this wide-ranging conversation, Stanford addiction expert and policy advisor Keith Humphreys returns to the show to walk us through what neuroscience has taught us about substance use disorders and how that science intersects with law, public health, and politics. From the biology of craving to the limits of autonomy, we explore the tension between compassion and accountability, and...
A generation ago, a big clot in the brain meant paralysis or worse. Today, doctors can diagnose clots on AI-enabled brain scans; provide life-saving, targeted medications; or snake a catheter from a patient’s groin into the brain to vacuum out the clot. If they intervene in time, they can watch speech and movement return before the sedatives wear off. How did that happen—and what’s still missing? In this episode of From Our Neurons to Yours, Stanford neuroscientist and neurocritical care spec...
We've all heard stories about someone who went in for surgery and came out...different. A grandmother who struggled with names after hip replacement, or an uncle who seemed foggy for months following cardiac bypass. But why does this happen to some people while others bounce right back? This week, we explore this question with Dr. Martin Angst, a professor of anesthesiology at Stanford who's studying the biological factors that determine cognitive outcomes after surgery. With support from the...
Imagine being trapped in your own body, unable to move or communicate effectively. This may seem like a nightmare, but it is a reality for many people living with brain or spinal cord injuries. We're re-releasing one of our favorite episodes from the archives: our 2024 conversation with Jaimie Henderson, a Stanford neurosurgeon leading groundbreaking research in brain-machine interfaces. Henderson shares how multiple types of brain implants are currently being developed to treat neurological...
This week on the show, we're have our sights set on healthy aging. What would it mean to be able to live to 80, 90 or 100 with our cognitive abilities intact and able to maintain an independent lifestyle right to the end of our days? We're joined by Beth Mormino and Anthony Wagner who lead the Stanford Aging and Memory Study, which recruits cognitively healthy older adults to understand what makes their brains particularly resilient — and how more of us could join them in living the dre...
This week on the show: Are we ready to create digital models of the human brain? Last month, Stanford researcher Andreas Tolias and colleagues created a "digital twin" of the mouse visual cortex. The researchers used the same foundation model approach that powers ChatGPT, but instead of training the model on text, the team trained in on brain activity recorded while mice watched action movies. The result? A digital model that can predict how neurons would respond to entirely new visual ...
If you spend any time chatting with a modern AI chatbot, you've probably been amazed at just how human it sounds, how much it feels like you're talking to a real person. Much ink has been spilled explaining how these systems are not actually conversing, not actually understanding — they're statistical algorithms trained to predict the next likely word. But today on the show, let's flip our perspective on this. What if instead of thinking about how these algorithms are not like the human...
We've talked about glia and sleep. We've talked about glia and neuroinflammation. We've talked about glia in the brain fog that can accompany COVID or chemotherapy. We've talked about the brain's quiet majority of non–neuronal cells in so many different contexts that it felt like it was high time for us to take a step back and look at the bigger picture. After all, glia science was founded here at Stanford in the lab of the late, great Ben Barres. No one is better suited to take us through th...
As we gain a better understanding of how misfiring brain circuits lead to mental health conditions, we'd like to be able to go in and nudge those circuits back into balance. But this is hard — literally — because the brain is encased in this thick bony skull. Plus, often the problem you want to target is buried deep in the middle of a maze of delicate brain tissue you need to preserve. Today we're going to be talking with neuroscientists who aim to solve this problem with sound. And not ...
We're kicking off our new season with a deep dive into one of neuroscience's most fascinating mysteries: sleep. This unconscious third of our lives isn't just about rest – it's absolutely critical for brain health, memory consolidation, and overall well-being. But here's where it gets intriguing: recent research suggests that increased napping as we age might be an early warning sign of Alzheimer's disease. To unpack this complex relationship, we're thrilled to welcome back Erin Gibson, assis...
Today, we are speaking with the one and only Robert Sapolsky, a Stanford neurobiologist, a MacArthur "Genius", and best-selling author of books exploring the nature of stress, social behavior, and — as he puts it — "the biology of the human predicament." In his latest book, Determined, Sapolsky assertively lays out his vision of a world without free will — a world where as much as we feel like we're making decisions, the reality is that our choices are completely determined by biological an...
Join us as we dive back into the world of psychedelic medicine with anesthesiologists Boris Heifets and Theresa Lii, who share intriguing new data that sheds light on how ketamine and placebo effects may interact in treating depression. We explore provocative questions like: How much of ketamine's antidepressant effect comes from the drug itself versus the excitement of being in a psychedelics trial? What do we know about how placebo actually works in the brain? And should we view the placebo...
Today, we are going back into the archives for one of my favorite episodes: We are talking to neuroscientist, entrepreneur, and best-selling author, David Eagleman. We're talking about synaesthesia — and if you don't know what that is, you're about to find out. Special Note We are beyond thrilled that From Our Neurons to Yours has won a 2024 Signal Award in the Science Podcast category. It's a big honor — thanks to everyone who voted! --- Imagine Thursday. Does Thursday have a color? What ...
Earlier this year, President Obama's signature BRAIN Initiative, which has powered advances in neuroscience for the past 10 years, had its budget slashed by 40%. Over the past decade, the BRAIN Initiative made roughly $4 billion in targeted investments in more than 1500 research projects across the country and has dramatically accelerated progress tackling fundamental challenges in neuroscience. As we head into the next federal budget cycle, the future of the initiative remains uncerta...
Given the widespread legalization of cannabis for medical and recreational uses, you'd think we'd have a better understanding of how it works. But ask a neuroscientist exactly how cannabinoid compounds like THC and CBD alter our perceptions or lead to potential medical benefits, and you'll soon learn just how little we know. We know that these molecules hijack an ancient signaling system in the brain called the "endocannabinoid" system (translation: the "cannabinoids within"). These somewhat...
2Today we are re-releasing an episode we did last year with Stanford neurobiologist Lisa Giocomo exploring the intersection of memory, navigation and the boundaries we create between ourselves and the world around us. This episode was inspired by the idea of memory palaces. The idea is simple: Take a place you're very familiar with, say the house you grew up in, and place information you want to remember in different locations within that space. When it's time to remember those things, you ca...
In the past few years, Big Pharma has released not one, but three new treatments for Alzheimer’s disease. Aducanemab (2021), Lecanemab (2023), and Donanemab (2024), are the first treatments to effectively clear the brain of amyloid plaques — the sticky protein clumps whose build-up in the brain has defined the disease for decades. The problem? They may not help patients at all. Today’s guest, Stanford neurologist Mike Greicius, considers the new amyloid-clearing drugs a major disappointment...
Comments
Download from Google Play
Download from App Store
United States